The FDA label record identified an indication-and-usage revision for Ocrevus Zunovo, effective August 17, 2026. The revised indication states that Ocrevus Zunovo is for treating relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The supplied drug field identifies amivantamab, while the headline and indication text identify Ocrevus Zunovo. This article follows the event-specific label text and does not infer that the revision applies to amivantamab.
Background
According to the FDA label summary, Ocrevus Zunovo is indicated for relapsing forms of multiple sclerosis. The covered disease categories are clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The indication applies to adults.
What this means
The revision provides a label-level statement of use for Ocrevus Zunovo across the specified relapsing forms of multiple sclerosis in adults. The supplied data do not include dosing instructions, clinical-trial results, comparative efficacy findings, safety outcomes, contraindications, or details about the wording changed elsewhere in the label.
Because the supplied record contains a mismatch between the listed drug name, amivantamab, and the product named in the headline and indication, readers should verify the product identity directly in the cited FDA label. The event date supplied for the revision is August 17, 2026.
Source
Source: FDA, DailyMed label record describing an indication-and-usage revision, effective August 17, 2026. The source is available through dailymed.nlm.nih.gov.